Engineering Papers⌕ Search

Engineering topics

Dugan, L. C.

Publications and source records attributed to Dugan, L. C..

BioID/LID System Cartridge Testing Report

LLNL produced two lots of lyophilized LAMP assay containing cartridges, LNL022818 and LNL071818, for testing on Gen3 BioID systems. Thirty-nine cartridges were tested for lot LNL022818. All thirty-nine cartridges performed as expected regarding correct positive control (IPC) and negative control (NTC) reactions. Five different templates were tested on these 39 cartridges. The BioID system detected 79.1% true positives and 9.3% false positives along with 98.9% true negatives and 2.9% false negatives for cartridge lot LNL022818. Thirty cartridges were tested for lot LNL071818. It was noted early that due to a manufacturing issue with the cartridges related to incomplete sonic welding of the cartridge, a large fraction of lot LNL071818 cartridges leaked. Insufficient funds were available to replace this lot of cartridges. Twenty three of 30 cartridges performed as expected regarding correct positive control (IPC) and negative control (NTC) reactions. Four different templates were tested on these 30 cartridges. The BioID system detected 77% true positives and 23% false positives along with 96.9% true negatives and 3.1% false negatives for cartridge lot LNL071818. For all tested cartridges using DNA template, DNA was added at a final concentration of 25 pg/ul. All reactions contained positive control DNA at 2.5 pg/ul.

42 ENGINEERING↗

Reveal-CoV Diaagnostic Platform (Final Report)

LLNL designed and built a rapid, RT-LAMP-based molecular diagnostics platform as a potential tool to quickly diagnose COVID-19 in under one hour. This point-of-care testing approach involves an initial high temperature swab sample inactivation step followed by amplification of viral RNA using up to 5 control and pathogen-specific assays. Results are determined based on a discreet reaction color change from red to yellow but can also be determined using fluorescence detection. Testing of this prototype platform was conducted with synthetic viral RNA and dried, stabilized reagents. Buffer systems, swab selection, and assay stabilization formulations were evaluated for performance. Limits of detection were determined using RNA; however, testing was not performed with viable SARS-CoV-2 virus or clinical samples.

59 BASIC BIOLOGICAL SCIENCES↗